SARS-CoV-2 mRNA vaccination exposes progressive adaptive immune dysfunction in patients with chronic lymphocytic leukemia.
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
20 Dec 2022
20 Dec 2022
Historique:
entrez:
4
1
2023
pubmed:
5
1
2023
medline:
5
1
2023
Statut:
epublish
Résumé
Chronic lymphocytic leukemia (CLL) patients have lower seroconversion rates and antibody titers following SARS-CoV-2 vaccination, but the reasons for this diminished response are poorly understood. Here, we studied humoral and cellular responses in 95 CLL patients and 30 healthy controls after two BNT162b2 or mRNA-2173 mRNA immunizations. We found that 42% of CLL vaccinees developed SARS-CoV-2-specific binding and neutralizing antibodies (NAbs), while 32% had no response. Interestingly, 26% were seropositive, but had no detectable NAbs, suggesting the maintenance of pre-existing endemic human coronavirus-specific antibodies that cross-react with the S2 domain of the SARS-CoV-2 spike. These individuals had more advanced disease. In treatment-naïve CLL patients, mRNA-2173 induced 12-fold higher NAb titers and 1.7-fold higher response rates than BNT162b2. These data reveal a graded loss of immune function, with pre-existing memory being preserved longer than the capacity to respond to new antigens, and identify mRNA-2173 as a superior vaccine for CLL patients.
Identifiants
pubmed: 36597532
doi: 10.1101/2022.12.19.22283645
pmc: PMC9810225
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : R37 AI150590
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA260462
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI069452
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
Science. 2021 Aug 13;373(6556):
pubmed: 34210892
Blood. 2022 Feb 3;139(5):678-685
pubmed: 34861036
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Blood. 2021 Jan 14;137(2):185-189
pubmed: 33259596
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
JAMA Netw Open. 2022 May 2;5(5):e2211897
pubmed: 35576009
Viruses. 2022 May 19;14(5):
pubmed: 35632836
J Infect Dis. 2022 Oct 17;226(8):1396-1400
pubmed: 36052810
Blood. 2013 Feb 28;121(9):1612-21
pubmed: 23247726
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
J Immunol. 1982 Nov;129(5):2305-12
pubmed: 6214590
Haematologica. 2022 Apr 01;107(4):1000-1003
pubmed: 35045694
Cell Rep Med. 2020 Dec 05;2(1):100164
pubmed: 33521696
Vaccine. 2018 Jun 14;36(25):3701-3707
pubmed: 29748028
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Cell Res. 2022 May;32(5):498-500
pubmed: 35292745
Emerg Infect Dis. 2021 Sep;27(9):2454-2458
pubmed: 34193339
N Engl J Med. 2000 Dec 28;343(26):1910-6
pubmed: 11136261
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Nat Biotechnol. 2015 Jun;33(6):610-6
pubmed: 26006008
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Vaccine. 2021 Feb 12;39(7):1122-1130
pubmed: 33461835
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
JAMA Oncol. 2016 Dec 1;2(12):1656-1657
pubmed: 27533065
Haematologica. 2017 Oct;102(10):e397-e399
pubmed: 28659336
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Clin Infect Dis. 2021 Jan 27;72(2):340-350
pubmed: 33501974
J Hematol Oncol. 2022 Jan 9;15(1):3
pubmed: 35000597
Blood Cancer Discov. 2022 Nov 2;3(6):481-489
pubmed: 36074641
Pathog Immun. 2021 Jun 7;6(1):116-134
pubmed: 34136730
Leukemia. 2021 Dec;35(12):3444-3454
pubmed: 34725454
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Blood. 1991 Sep 15;78(6):1569-73
pubmed: 1679357
Eur J Immunol. 2008 Nov;38(11):3159-66
pubmed: 18991291
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
PLoS Pathog. 2021 Jul 16;17(7):e1009761
pubmed: 34270631
Cell. 2019 Apr 18;177(3):524-540
pubmed: 31002794
Immunity. 2016 Sep 20;45(3):471-482
pubmed: 27653600
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1105-1110
pubmed: 28096374
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Blood. 2015 Jul 30;126(5):573-81
pubmed: 26084672
Nat Biomed Eng. 2020 Dec;4(12):1134-1139
pubmed: 33293725
Cell. 2021 Aug 5;184(16):4220-4236.e13
pubmed: 34242578
Blood. 2022 Aug 4;140(5):445-450
pubmed: 35588468
Cancer Cell. 2021 Aug 9;39(8):1031-1033
pubmed: 34331856
Protein Eng Des Sel. 2022 Feb 17;35:
pubmed: 35174857
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Cell Rep Med. 2021 Feb 16;2(2):100204
pubmed: 33521695
Eur J Haematol. 2019 Jun;102(6):447-456
pubmed: 30801785
Leukemia. 2021 Mar;35(3):737-746
pubmed: 32555297
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Cell Host Microbe. 2019 Mar 13;25(3):357-366.e6
pubmed: 30795982
ACS Cent Sci. 2021 Apr 28;7(4):512-533
pubmed: 34056083